danticorps

Danticorps is a term that appears in some contemporary sources to describe engineered antibody-like molecules or synthetic antibodies designed to target specific antigens. In established immunology, this term is not standard; the conventional terms are anticorps in French or antibodies in English, including subtypes such as monoclonal antibodies, antibody fragments, and bispecific antibodies.

Usage and scope: Depending on the source, danticorps may refer to different concepts: engineered antibodies produced by recombinant DNA technology; in vivo expressed antibodies delivered by gene therapy; or compact binding proteins such as nanobodies and single-chain variable fragments that are framed as danticorps. The common thread is antigen recognition via variable regions and the potential to recruit immune effector functions.

Production and applications: Danticorps are typically produced in cell culture systems or encoded in vectors for in vivo expression. They are explored in research and therapeutic contexts for infectious diseases and cancer, and in diagnostics for antigen detection. However, their use depends on advances in delivery, specificity, pharmacokinetics, and safety.

Limitations and regulatory status: As with antibodies in general, danticorps face challenges including immunogenicity, off-target effects, manufacturing complexity, and regulatory oversight before clinical use.

See also: Antibody, Monoclonal antibody, Nanobody, Bispecific antibody, Immunotherapy, Gene therapy.